Retina Vitreous Associates Medical Group
Retina Vitreous Associates Medical Group was paid $24.03M by Medicaid between Jan 2018 and Dec 2024, across 28 billing codes. Its largest line is 67028, Intravitreal injection of a pharmacologic agent — 28% of everything it billed.
33Billing provider infoRETINA VITREOUS ASSOCIATES MEDICAL GROUP
LOS ANGELES, CA 90017
LOS ANGELES, CA 90017
33aNPI1134164023assigned 06/17/2006
33bProvider typeSpecialist
28Total paid$24.03M
24GClaims401,533
24DCodes billed28
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in California
Rank by total paid#2 of 1,230
Median peer was paid$51K
This provider vs. median468×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,194 | $1.97M | |
| 2019 | 57,390 | $2.92M | |
| 2020 | 51,410 | $3.29M | |
| 2021 | 54,569 | $3.69M | |
| 2022 | 56,463 | $3.92M | |
| 2023 | 71,167 | $4.62M | |
| 2024incomplete | 61,340 | $3.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 67028 | Intravitreal injection of a pharmacologic agent | 28% | 63,561 | 59,754 | $6.80M |
| J0178 | Injection, aflibercept, 1 mg | 23% | 10,788 | 10,386 | $5.41M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 12% | 66,728 | 64,703 | $2.91M |
| 92134 | 7.3% | 121,247 | 115,255 | $1.76M | |
| J9035 | Injection, bevacizumab, 10 mg | 7.0% | 31,518 | 29,577 | $1.69M |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 6.6% | 4,699 | 4,551 | $1.59M |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 6.1% | 34,024 | 32,510 | $1.47M |
| J2778 | Injection, ranibizumab, 0.1 mg | 2.6% | 1,697 | 1,643 | $634K |
| J2777 | Injection, faricimab-svoa, 0.1 mg | 1.9% | 872 | 847 | $448K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.2% | 6,924 | 6,920 | $289K |
| 92202 | <1% | 21,525 | 21,163 | $161K | |
| 92235 | <1% | 5,410 | 5,072 | $161K |
16 more codes
| 92226 | <1% | 10,508 | $139K | |
| J3490 | Unclassified drugs | <1% | 286 | $128K |
| 92250 | <1% | 6,581 | $91K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 2,776 | $76K |
| 76512 | <1% | 2,524 | $63K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 2,034 | $61K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,612 | $54K |
| 92225 | <1% | 2,161 | $26K | |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | <1% | 43 | $20K |
| 92201 | <1% | 2,340 | $19K | |
| 67228 | <1% | 95 | $14K | |
| J0177 | Injection, aflibercept hd, 1 mg | <1% | 14 | $8K |
| 99024 | <1% | 1,402 | $5K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 126 | $3K |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | <1% | 24 | $584.08 |
| 76510 | <1% | 14 | $384.10 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOYER, DAVID (PARTNER)
| Provider | Location | Paid |
|---|---|---|
| Seeds of Change Counseling Services, LLC. | Eugene, OR | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.